Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Read recent data presented at #SNMMI24 as we advance our Actimab program: https://bit.ly/3Ro0ikZ
Actinium Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
Webinar tomorrow!! Still using hybridoma? Sequencing and re-expressing thousands of useless hits? You don’t need to! Register below and find out why Beacon is both the present AND future gold standard in antibody discovery! #bruker #beacon #antibodydiscovery #singlecellanalysis #nextgenai
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
To view or add a comment, sign in
-
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery | Bruker Cellular Analysis
To view or add a comment, sign in
-
Join us Feb 28 the upcoming Webinar to learn how Beacon technology enables raipd discovery of monicolonal antibodies across different species and B cell sources!!!
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0
Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery | Bruker Cellular Analysis
To view or add a comment, sign in
-
AD | Introducing a monoclonal ANTI-FLAG® M2 #antibody. Unlike the ANTI-FLAG® M1 antibody, the M2 antibody recognizes the FLAG® sequence at the N-terminus, Met-N-terminus, C-terminus, or an internal site of FLAG® #fusionproteins. Use it to identify and capture FLAG® fusion proteins through #Westernblot, #immunoprecipitation, and #immunofluorescence. -> https://bit.ly/4baqya4
To view or add a comment, sign in
-
SMARCA4/2 ATPase Inhibitor causes a selective reversal of T cell exhaustion
SITC 2023 Poster 1119
crownbio.com
To view or add a comment, sign in
-
Today, we announced our strategic updates for 2024. As we enter 2024, we have several milestones ahead of us, including anticipated data from our FHD-286 combination study in acute myeloid #leukemia (AML), pre-clinical combination data with FHD-286 and tyrosine kinase inhibitors (TKIs) in EGFR/KRAS resistance, and preclinical data from our selective EP300 and CBP programs. We have made significant progress with our preclinical pipeline, advancing our BRM selective inhibitor and #proteindegrader programs in collaboration with LoxoLilly, as well as our selective ARID1B program. Learn more about our research progress and outlook for 2024: https://bit.ly/48MKJcv #biotechnology #innovation #JPM24 #JPM2024
To view or add a comment, sign in
-
evitria’s journal club - paper of the week no. 5 Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations (June 2022) from George Delidakis et al. When undertaking an Fc optimization study, it is always important to consider what mechanism of action you are working with, and design your constructs accordingly. This review brilliantly connects Fc engineering strategies with Fc receptor interactions and downstream effector functions. Access the review and learn more about how our team can support your Fc optimization work here: https://lnkd.in/e6vUEtfU #antibodies #antibodyengineering
Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations
linkedin.com
To view or add a comment, sign in
-
Antibody-Drug-Conjugate (ADC) efficacy is often hampered by instable linkage of the drug and the antibody, causing the drug to be released in circulation and thus leading to off-target toxicity. Marc-André Kasper explained how Tubulis GmbH tackles this challenge with their unique #ADC development technologies in our previous #webinar episode. Watch the recording on YouTube to find out more about 💡 next generation ADCs with superior stability 💡 whether binding to the cellular receptor is affected by conjugation and how this can be assessed by Real-Time Interaction Cytometry (#RTIC) 💡 how the #switchSENSE dynamic measurement mode can help draw conclusions on #tumor penetration of ADCs 🎥 https://lnkd.in/dr3dkAd4 Not interested in ADCs? 👉 Visit https://lnkd.in/eVKkGBgG to find a bunch of other topics in future episodes. (Spoiler: next month we will talk about #PROTACs and ternary complex kinetics 👍) #DiscoverMolecularInteractions
DISCOVER therapeutic antibodies: kinetics of antibody-drug conjugates measured directly on cells
https://www.youtube.com/
To view or add a comment, sign in
-
𝗪𝗵𝗶𝗰𝗵 𝗖𝗵𝗶𝗺𝗲𝗿𝗶𝗰 𝗔𝗻𝘁𝗶𝗴𝗲𝗻 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 (𝗖𝗔𝗥) 𝗕𝗶𝗻𝗱𝗶𝗻𝗴 𝗱𝗼𝗺𝗮𝗶𝗻 𝗱𝗼 𝘆𝗼𝘂 𝘁𝗵𝗶𝗻𝗸 𝗶𝘀 𝗯𝗲𝘀𝘁? The Classical single chain variable fragment (scFv) CAR is the best thing since sliced bread, but what are the alternatives? Various other binding domains such as; DARPins, Llama (🐪) derived Nanobodies, Wild-type Receptors or Ligands and De novo recognition elements all show promising results with their own unique advantages and disadvantages over classical scFv CARs. Reference: Nix, M.A. & Wiita, A.P. (2024) Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy. 2:S1465-3249(24)00069-0. doi: 10.1016/j.jcyt.2024.02.024. Epub ahead of print. PMID: 38466264.
To view or add a comment, sign in
-
What is ELISpot? ELISpot stands for Enzyme-Linked ImmunoSpot. This powerful assay detects and quantifies individual cells secreting specific cytokines, immunoglobulins, or other targeted proteins. Using extremely specific monoclonal antibody pairs, few assays can rival ELISpot’s sensitivity. See the assay principle below! #ELISpot #ImmunoAssay
To view or add a comment, sign in
12,797 followers